BiotechTube

Romiplostim (AMG-531)

Phase 2Completed
2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Conditions

Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Trial Timeline

Feb 1, 2006 → Nov 1, 2006

NCT ID
NCT00305435

About Romiplostim (AMG-531)

Romiplostim (AMG-531) is a phase 2 stage product being developed by Kyowa Kirin for Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP). The current trial status is completed. This product is registered under clinical trial identifier NCT00305435. Target conditions include Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP).

What happened to similar drugs?

2 of 20 similar drugs in Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) were approved

Approved (2) Terminated (2) Active (16)
✅Standard heparin (UFH) versus certoparin (LMWH)NovartisApproved
✅romiplostimAmgenApproved
🔄avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
🔄avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
🔄Avatrombopag + Placebo + Standard of careEisaiPhase 3
🔄Romiplostim + PlaceboKyowa KirinPhase 3
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00305435Phase 2Completed

Competing Products

20 competing products in Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + PlaceboEli LillyPhase 1/2
39
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
17
Placebo + LusutrombopagShionogiPhase 2
27
LusutrombopagShionogiPhase 2
27
Avatrombopag + Avatrombopag + PlaceboEisaiPhase 2
35
avatrombopagEisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
40
avatrombopag + PlaceboEisaiPhase 2
35
Avatrombopag + Placebo + Pegylated interferon (PEG-IFN) + Telaprevir + RibavirinEisaiPhase 2
35
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
40
Avatrombopag + Placebo + Standard of careEisaiPhase 3
40
RomiplostimKyowa KirinPhase 1/2
32
Romiplostim + PlaceboKyowa KirinPhase 3
40
Romiplostim and danazolKyowa KirinPhase 2
31
ONO-7746Ono PharmaceuticalPhase 1
21
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
29
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
47
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 2
42
TPO-RA (Herombopag) + TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)Jiangsu Hengrui MedicinePhase 2
31